Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2628280-40-8
Molecular formula
C23H32F3N5O4
Molecular weight
499.5 g/mol
Drug class
SARS-CoV-2 main protease (3CLpro/Mpro) inhibitorantiviral component of Paxlovid
Mechanism of action
Selectively inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication. It is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases nirmatrelvir exposure.
Indications / reported uses
In combination with ritonavir (PAXLOVID) for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalisation or death, under the applicable product label; nirmatrelvir monotherapy is not the authorised regimen
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Nirmatrelvir Environmental Risk Assessment (ERA) (the Nirmatrelvir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.